# Invesco Biotechnology & Genome ETF (PBE): ETF Facts & Distributions > Markdown mirror of https://www.dividenddata.com/funds/pbe for AI agents. Same live data as the HTML page, regenerated on the same refresh cycle. Not investment advice. - Issuer: Invesco · Asset class: Equity - Strategy: Thematic · Inception: 2005-06-23 The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily in... ## Key Facts | Metric | Value | |---|---| | Price | $101.87 | | Expense Ratio | 0.59% | | Assets Under Management | $431.9M | | NAV | $99.28 | | Holdings Count | 31 | | Distribution Yield (TTM) | 1.31% | | Annual Distribution (TTM) | $1.33 /share | | Distribution Frequency | Quarterly | | 52-Week Range | $72.27 – $102.18 | | Beta | 0.79 | ## Latest Distribution - Amount: $0.0187 /share - Ex-date: 2026-09-21 - Pay date: 2026-09-25 ## Frequently Asked Questions ### What does PBE invest in? The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily involved in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, or they are businesses that stand to gain significantly from scientific and technological breakthroughs in biotechnology and genetic engineering. Both the ETF and its benchmark index undergo quarterly rebalancing and reconstitution in February, May, August, and November. ### What is the expense ratio of PBE? Invesco Biotechnology & Genome ETF (PBE) charges an expense ratio of 0.59%. This is the annual fee deducted from fund assets to cover management and operations. ### How big is PBE? Invesco Biotechnology & Genome ETF (PBE) manages $431.9M in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure. Funds below ~$50M are at higher risk of liquidation. ### Is PBE actively managed or an index fund? PBE's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy. ### When was PBE launched? Invesco Biotechnology & Genome ETF (PBE) launched in June 2005 and is managed by Invesco. ### How has PBE performed? PBE's total return (price change plus reinvested distributions) is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon. ### Does PBE pay a dividend? Invesco Biotechnology & Genome ETF (PBE) currently distributes little or no income. Trailing-twelve-month yield is 1.31%. Investors looking for income should consider income-focused alternatives. See the Peers tab. ### How often does PBE pay dividends? Invesco Biotechnology & Genome ETF pays dividends Quarterly. Each ex-dividend date, record date, and payment date is listed in the dividend history table on this page. ### What is PBE's dividend yield? PBE's trailing-twelve-month yield is 1.31%, calculated from the sum of dividends over the past year divided by the current price. ### When is PBE's next ex-dividend date? The most recently announced ex-dividend date for PBE was 2026-09-21. The next ex-date typically follows Quarterly; once announced it appears at the top of the dividend history table on this page. ### How much will PBE's expense ratio cost me over 30 years? On a $10,000 investment compounding at 7% gross return, a 0.59% expense ratio quietly compounds against your balance every year. The Fee Compounding Forecast card above projects the dollar drag for any holding period and assumption you pick. The typical result for a 1.0% expense ratio on a 30-year hold is roughly 25% of the final balance lost to fees. ### How does PBE charge its expense ratio? The expense ratio is deducted in tiny daily slices from PBE's net asset value (NAV). You never see a bill. The price quoted on every exchange is already net of fees. There's no "fee day" to avoid; the cost is continuous and built into the trading price. ### Why does PBE cost more than a fund like VOO? PBE's strategy (current expense ratio 0.59%) is different from a broad-market index tracker like VOO, so its fee belongs to a different cohort. The Cost Verdict card above shows you where PBE sits within its own category, which is the comparison that actually matters. ### Are there cheaper alternatives to PBE? The Lower-Fee Alternatives card above lists ETFs following the same investment strategy as PBE (0.59%) but at a lower expense ratio. Each row shows the fee gap, the peer's AUM as a liquidity sanity-check, and a direct link to that fund's analysis page. Cheaper price doesn't automatically mean better. Verify the peer holds what you actually want. ## More on Dividend Data - Overview (HTML): https://www.dividenddata.com/funds/pbe - Distribution history: https://www.dividenddata.com/funds/pbe/dividend - Holdings & diversification: https://www.dividenddata.com/funds/pbe/diversification - Fees & cheaper alternatives: https://www.dividenddata.com/funds/pbe/expenses - Peer comparison: https://www.dividenddata.com/funds/pbe/peers Data sourced from primary filings and market data providers; see https://www.dividenddata.com/methodology.